Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Cognat

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Alzheimer'S Research & Therapy|May 14, 2026
Clinical correlates of sleep profiles in dementia with Lewy bodies: a latent class approachLéa Renard, Clément Aveneau, Karl Götze, et al.
International Journal of Bipolar Disorders|December 31, 2024
Brain 18FDG-PET pattern in cognitively impaired elderly patients with bipolar disorderNouredine Saleh, Capucine Blaise, Amina Daoudi, et al.
Alzheimer'S Research & Therapy|May 23, 2022
Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort studyAgathe Vrillon, François Mouton-Liger, Matthieu Martinet, et al.
International Journal of Molecular Sciences|November 11, 2022
Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer's Disease in Clinical PracticeMatthieu Lilamand, Josué Clery, Agathe Vrillon, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2015
Potassium channelopathy-like defect underlies early-stage cerebrovascular dysfunction in a genetic model of small vessel diseaseFabrice Dabertrand, Christel Krøigaard, Adrian D Bonev, et al.
Alcoholism, Clinical and Experimental Research|January 24, 2021
Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive ImpairmentJulien Azuar, Elodie Bouaziz-Amar, Emmanuel Cognat, et al.
Clinical Chemistry and Laboratory Medicine|August 30, 2025
Cerebrospinal fluid leptin in Alzheimer's disease: relationship to plasma levels and to cerebrospinal amyloidElodie Bouaziz-Amar, Jeanne Neez, Fidaa Ibrahim, et al.
Alzheimer'S Research & Therapy|March 30, 2019
CSF level of β-amyloid peptide predicts mortality in Alzheimer's diseaseAdla Boumenir, Emmanuel Cognat, Severine Sabia, et al.
Journal of Alzheimer'S Disease : JAD|October 22, 2025
Cerebrospinal fluid acetylcholine is not a reliable diagnostic marker for Alzheimer's disease and dementia with Lewy bodiesClément Aveneau, Elodie Lamy, Stanislas Grassin-Delyle, et al.
Journal of Neurology|March 24, 2026
Eligibility for lecanemab treatment in a French memory clinic settingAgathe Vrillon, Karl Götze, Julien Dumurgier, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Alzheimer'S Research & Therapy|May 14, 2026
Clinical correlates of sleep profiles in dementia with Lewy bodies: a latent class approachLéa Renard, Clément Aveneau, Karl Götze, et al.
International Journal of Bipolar Disorders|December 31, 2024
Brain 18FDG-PET pattern in cognitively impaired elderly patients with bipolar disorderNouredine Saleh, Capucine Blaise, Amina Daoudi, et al.
Alzheimer'S Research & Therapy|May 23, 2022
Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort studyAgathe Vrillon, François Mouton-Liger, Matthieu Martinet, et al.
International Journal of Molecular Sciences|November 11, 2022
Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer's Disease in Clinical PracticeMatthieu Lilamand, Josué Clery, Agathe Vrillon, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2015
Potassium channelopathy-like defect underlies early-stage cerebrovascular dysfunction in a genetic model of small vessel diseaseFabrice Dabertrand, Christel Krøigaard, Adrian D Bonev, et al.
Alcoholism, Clinical and Experimental Research|January 24, 2021
Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive ImpairmentJulien Azuar, Elodie Bouaziz-Amar, Emmanuel Cognat, et al.
Clinical Chemistry and Laboratory Medicine|August 30, 2025
Cerebrospinal fluid leptin in Alzheimer's disease: relationship to plasma levels and to cerebrospinal amyloidElodie Bouaziz-Amar, Jeanne Neez, Fidaa Ibrahim, et al.
Alzheimer'S Research & Therapy|March 30, 2019
CSF level of β-amyloid peptide predicts mortality in Alzheimer's diseaseAdla Boumenir, Emmanuel Cognat, Severine Sabia, et al.
Journal of Alzheimer'S Disease : JAD|October 22, 2025
Cerebrospinal fluid acetylcholine is not a reliable diagnostic marker for Alzheimer's disease and dementia with Lewy bodiesClément Aveneau, Elodie Lamy, Stanislas Grassin-Delyle, et al.
Journal of Neurology|March 24, 2026
Eligibility for lecanemab treatment in a French memory clinic settingAgathe Vrillon, Karl Götze, Julien Dumurgier, et al.
Pageof 9